Wealth terciles were constructed using the final asset scores, which were based on an analysis of the whole sample, including baseline and endline participants, to control for socio-economic differences between the two groups.
Separately the entire nilotinib dataset comprising expression data for 24 samples (including all baseline, 6-month and 12-month biopsies) was combined with 4 healthy control samples analyzed on the same DNA microarray platform to provide the proper data distribution across groups.
For the current study we analysed stored baseline samples (including a subset previously described 14) and the follow-up samples, enabling repeat testing for HPV.
Baseline blood samples, including fasting lipid profiles (total cholesterol, triglycerides (TGs), and high-density lipoproteins (HDLs)), erythrocyte sedimentation rate (ESR), C-reactive protein, fasting glucose, insulin, and rheumatoid factor, were taken.
Biological samples, including blood and urine, were collected at baseline, along with clinical and covariate data.
These include baseline correction, smoothing/denoising, data binning, peak alignment, peak detection and sample normalisation.
PATIENT SAMPLE: Studies included subjects aged 18 years or older, from longitudinal, observational, cohort designs that included baseline risk factors to an outcome of either first-time LBP or transition to LBP from a baseline of a pain-free state.
The remaining 58 patients had at least two blood samples collected, including a baseline sample, and were included in the analysis.
Samples include: PC World.
The baseline sample includes 6,804 bilateral observations plus 625 grouped observations.
